pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca clinical programs — 249 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
AstraZeneca projects
249 ClinicalTrials.gov programs sponsored by AstraZeneca.
AstraZeneca has 249 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Rilvegostomig, Rilvegostomig
AstraZeneca AB
Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).
1 trial -
SAVANNAH
AstraZeneca AB
EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
1 trial -
SAVANNAH/D5084C0007
AstraZeneca AB
EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer
1 trial -
SPRINKLE D1346C00004
AstraZeneca AB
Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
1 trial -
Saruparib
AstraZeneca AB
Advanced/Recurrent Ovarian cancer
1 trial -
ZEAL-UNLOCK
AstraZeneca AB
Cirrhosis of the liver is a condition in which the liver is scarred and damaged
1 trial -
D798VC00001
AstraZeneca AB
Colorectal cancer
1 trial -
A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors
AstraZeneca AB
Advanced solid tumours
1 trial -
A trial to learn how baxdrostat affects the heartbeat in healthy participants
AstraZeneca AB
Treatment-resistant hypertension, Primary aldosteronism, Uncontrolled hypertension
1 trial -
AZD5462-D9090C00012
AstraZeneca AB
Chronic Heart Failure
1 trial -
AZD5492
AstraZeneca AB
B-Cell Malignancies
1 trial -
An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients
AstraZeneca AB
Breast Cancer
1 trial -
D0816C00025
AstraZeneca AB
solid tumors
1 trial -
D1346C00015
AstraZeneca AB
Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
1 trial -
D3560C00817
AstraZeneca AB
Clinical trial healthy volunteer
1 trial -
D3615C00005
AstraZeneca AB
Healthy participants
1 trial -
D5084C00016
AstraZeneca AB
Healthy Volunteers
1 trial -
D533BC00003
AstraZeneca AB
Advanced solid tumour
1 trial -
D5985C00008
AstraZeneca AB
Not applicable, healthy volunteers
1 trial -
D5985C00009
AstraZeneca AB
Not applicable, healthy volunteers
1 trial -
D6830C00004
AstraZeneca AB
Asthma
1 trial -
D702EC00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D7260C00007
AstraZeneca AB
Not applicable, healthy volunteers
1 trial -
D740AC00001
AstraZeneca AB
Systemic Lupus Erythematosus, Rheumatoid Arthritis
1 trial -
D7860C00004
AstraZeneca AB
Chronic obstructive pulmonary disease
1 trial -
D7860C00005
AstraZeneca AB
Type 2 Diabetes Mellitus
1 trial -
D7930C00003
AstraZeneca AB
advanced liver fibrosis
1 trial -
D8210C00006
AstraZeneca AB
Asthma
1 trial -
D8330C00004
AstraZeneca AB
Heart failure with reduced ejection fraction, Renal impairment
1 trial -
D8340C00001
AstraZeneca AB
PLN R14del Dilated Cardiomyopathy
1 trial -
D8530C00001
AstraZeneca AB
"Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"
1 trial -
D8990C00001
AstraZeneca AB
Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.
1 trial -
D8991C00002
AstraZeneca AB
Ovarian cancer Primary peritoneal cancer Fallopian tube cancer
1 trial -
D907HC00001
AstraZeneca AB
• Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer
1 trial -
D9090C00007
AstraZeneca AB
Moderate Renal Impairment, Heart Failure
1 trial -
D9090C00010
AstraZeneca AB
Impaired renal function
1 trial -
D9180C00006
AstraZeneca AB
Inflammation, Respiratory
1 trial -
D9180C00011
AstraZeneca AB
healthy volunteers
1 trial -
D926FC00001
AstraZeneca AB
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
D933IC00001
AstraZeneca AB
Metastatic Non-Small Cell Lung Cancer (NSCLC)
1 trial -
D9440C00003
AstraZeneca AB
Healthy Volunteers, Renal Impairment and End Stage Kidney Disease
1 trial -
D9441C00001
AstraZeneca AB
Chronic Kidney disease, Atherosclerotic Cardiovascular Disease
1 trial -
D9441C00004
AstraZeneca AB
Cardiorenal disease
1 trial -
D9470C00001
AstraZeneca AB
CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.
1 trial -
D9609C00001
AstraZeneca AB
Healthy Volunteers
1 trial -
D9640C00001
AstraZeneca AB
Rheumatoid Arthritis
1 trial -
D967JC00002
AstraZeneca AB
Metastatic Breast Cancer
1 trial -
D967YC00001
AstraZeneca AB
Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)
1 trial
Frequently asked questions
How many clinical projects does AstraZeneca have?
249 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.